Dr Pshezhetskiy has received an MSc (summa cum laude) from Lomonosov Moscow State University in 2000. He has completed his PhD in Moscow State/Montreal Universities in 2003 and has carried out post-doctoral research in Paul Sabatier University, Toulouse (2003-2005) and CNRS Institute of Structural Biology and Pharmacology, Toulouse (2005-2006). During this period, he also worked as a visiting scientist at McGill University, Canada. In 2006 Dr Pshezhetskiy joined Imperial College London as a Research Fellow/Head of the Tumour Microenvironment and Chemotherapy group. Since April 2012 he has held an Honorary Senior Lectureship at the Norwich Medical School, UEA. His current research interests include the molecular mechanisms of cancer pathogenesis, inflammatory response, cancer biomarkers and novel targeted therapies.
Dr Pshezhetskiy is involved in teaching and supervision. He acts as a lecturer for several programmes in biology and cancer and has supervised many MSc, MRes and PhD projects. He acts as a PhD thesis examiner at Imperial College London and University of Kent and is a narrator and question reviewer for Imperial College/Lee Kong Chian School of Medicine, Singapore.
Dr Pshezhetskiy is an associate editor and a member of editorial board for several journals including American Journal of Cancer Research. He acts as a reviewer for many international scientific journals (JCO, Oncogene, etc), trusts (such as Wellcome trust) and research councils (such as MRC).
Dr Pshezhetskiy is a recipient of many prizes and awards including: EACR Mike Price young scientist award 2005, Wellcome Trust Value in People award 2011, BACR AstraZeneca Young Scientist Frank Rose Award and Lecture at NCRI 2011, and Foulkes fellowship for excellence in academic medicine 2012-2015
<- Page 1 of 3 ->
New FTY720-docetaxel nanoparticle therapy overcomes FTY720-induced lymphopenia and inhibits metastatic breast tumour growth,
in Breast Cancer Research and Treatment
pp. 531–543Full Text UEA Repository
Core shell lipid-polymer hybrid nanoparticles with combined docetaxel and molecular targeted therapy for the treatment of metastatic prostate cancer,
in Scientific Reports
article no. 5901Full Text UEA Repository
Combination of RAD001 (everolimus) and docetaxel reduces prostate and breast cancer cell VEGF production and tumour vascularisation independently of sphingosine-kinase-1,
in Scientific Reports
article no. 3493Full Text UEA Repository
An unusual case of disseminated intravascular coagulation,
in Oxford Medical Case Reports
article no. omx009Full Text UEA Repository
Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1,
pp. 80943-80956Full Text UEA Repository
Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer,
in Journal of Cancer Research and Clinical Oncology
pp. 1659–1671Full Text
Leptomeningeal carcinomatosis as the primary presentation of relapse in breast cancer,
in Oncology Letters
pp. 779-782Full Text
miR-515-5p controls cancer cell migration through MARK4 regulation,
in EMBO reports
pp. 570-584Full Text UEA Repository
The emerging role of FTY720 (Fingolimod) in cancer treatment,
pp. 23106-23127Full Text
Leptin signalling, obesity and prostate cancer: molecular and clinical perspective on the old dilemma,
pp. 35556-35563Full Text UEA Repository
Sphingosine kinase 1 contributes to leptin-induced STAT3 phosphorylation through IL-6/gp130 transactivation in oestrogen receptor-negative breast cancer,
in Breast Cancer Research and Treatment
pp. 59-67Full Text UEA Repository
Leptin receptor-dependent and -independent STAT3 phosphorylation in oestrogen receptor-negative breast cancer,
in International Journal of Molecular Medicine
Leptin induces upregulation of sphingosine kinase 1 in oestrogen receptor-negative breast cancer via Src family kinase-mediated, janus kinase 2-independent pathway,
in Breast Cancer Research
article no. 426Full Text UEA Repository
Spontaneous antibodies against Engrailed-2 (EN2) protein in patients with prostate cancer,
in Clinical and Experimental Immunology
pp. 428-38Full Text UEA Repository
Castrate-resistant prostate cancer: the future of antiandrogens,
in Trends in Urology & Men’s Health
Chapter Six – Therapeutic Potential of Targeting SK1 in Human Cancers,
in Advances in Cancer Research : The Role of Sphingolipids in Cancer Development and Therapy.
ISBN 978-0-12-394274-6Full Text
Differential control of hypoxia-inducible factor 1 activity during pro-inflammatory reactions of human haematopoietic cells of myeloid lineage,
in International Journal of Biochemistry & Cell Biology
pp. 1739-49Full Text UEA Repository
Apelin prevents cardiac fibroblast activation and collagen production through inhibition of sphingosine kinase 1,
in European Heart Journal
pp. 2360-9Full Text UEA Repository
A metabolic phenotyping approach to understanding relationships between metabolic syndrome and breast tumour responses to chemotherapy,
in Annals of Oncology
pp. 860-866Full Text UEA Repository
TGFβ1-Endo180-dependent collagen deposition is dysregulated at the tumour-stromal interface in bone metastasis,
in The Journal of Pathology
pp. 775-783Full Text UEA Repository
<- Page 1 of 3 ->
Key Research Interests
Dmirty’s research is focused on the identification of molecular mechanisms of prostate cancer chemoresistance and metastasis and finding novel therapies to treat the disease. The team are focused on a tumour-promoting protein called sphingosine kinase-1 or SK1. Prostate cancer cells have more SK1 than normal prostate cells, which allows cancer cells to grow faster and move faster. SK1 also helps cancer cells protect themselves against current treatments. Unfortunately, it is not understood how SK1 has these effects in prostate cancer cells. However, the team recently found that SK1 acts as a sensor to therapy in prostate cancer.
The success of a therapy was dependent on its ability to switch SK1 off. The introduction of specific drugs that target SK1 was found to enhance the effects of standard chemotherapy and radiotherapy. Furthermore, in recent findings the group have revealed a set of SK1-regulated proteins present in the plasma of patients that allows for improved early detection of prostate cancer. The groups work will help to identify and develop new drugs that may provide benefit for prostate cancer patients by improving survival in men with recurrent prostate cancer and bringing a decisive change to the way we treat prostate cancer in the future.
Current projects include:
The investigation of SK1 functions in prostate cancer cells The development of a targeted nanoparticle system for multi-component drug delivery to provide a new chemotherapetic modality for patients with hormone refractory/chemoresistant prostate cancer (collaboration with Colin Cooper).
There are potential PhD projects available, for inquiries please mail email@example.com
- Pchejetski D, Alshaker H, Stebbing J. Castrate resistant prostate cancer: the future of anti-androgens. Trends in Urology & Men’s Health – Nov 2013.
- Pinho F, Krell J, Nunes J, Frampton A, Alshaker H, Jacob J, Waxman J, Stebbing J, Pchejetski D*, Castellano L* (*- equal contribution). microRNA-515-5p is downregulated by the estrogen receptor leading to enhanced Sphingosine Kinase 1 mediated proliferation in breast cancer. Cancer Res. 2013 Oct 1;73(19):5936-5948
- Alshaker H, Sauer L, Monteil D, Ottaviani S, Srivats S, Böhler T, Pchejetski D. Therapeutic Potential of Targeting SK1 in Human Cancers. Adv Cancer Res. 2013;117:143-200.
- Gibbs BF, Yasinska IM, Pchejetski D, Wyszynski, RW, Sumbayev VV. Differential control of hypoxia-inducible factor 1 activity during pro-inflammatory reactions of human hematopoietic cells of myeloid lineage. Int. J Biochem & Cell Biol 2012, Epub ahead of print
- Nunes J, Naymark M, Sauer L, Muhammad A, Keun H, Sturge J, Stebbing J, Waxman J, Pchejetski D. Circulating sphingosine-1-phosphate and erythrocyte sphingosine kinase-1 activity as novel biomarkers for early prostate cancer detection. Br J Cancer 2012 Feb 7. doi: 10.1038/bjc.2012.14.
- Stebbing J, Sharma A, North B, Zebrowski A, Pchejetski D, Coombes C, Nicholson J, Keun H. A metabolic phenotyping approach to understanding relationships between metabolic syndrome and breast tumor responses to chemotherapy. Ann Oncol. 2012 Apr;23(4):860-6.
- Caley MP, Kogianni G, Adamarek A, Gronau JH, Rodriguez-Teja M, Fonseca AV, Mauri F, Sandison A, Rhim JS, Pchejetski D, Palmieri C, Cobb JP, Waxman J, Sturge J.TGF?1-Endo180-dependent collagen deposition is dysregulated at the tumour-stromal interface in bone metastasis. J Pathol. 2012 Apr;226(5):775-83.
- Pchejetski D, Böhler T, Stebbing J, WaxmanJ. Therapeutic potential of targeting sphingosine kinase 1 in prostate cancer. Nat Rev Urol. 2011 Sep 13;8(10):569-678.
- Pchejetski D, Foussal C, Alfarano C, Calise D, Guilbeau-Frugier C, Seguelas MH, Valet P, Parini A, Kunduzova O. Apelin prevents cardiac fibroblast activation and collagen production through inhibition of sphingosine kinase 1. Eur Heart J. 2011 Oct 25.
- Pchejetski D, Nunes J, Coughlan K, Lall H, Pitson SM, Waxman J and Sumbayev VV. The involvement of sphingosine kinase 1 in LPS-induced Toll-like receptor 4- mediated accumulation of HIF-1 alpha protein, activation of ASK1 and production of the pro-inflammatory cytokine IL-6. Immunol Cell Biol, 2011 Feb;89(2):268-74
FCT Petra University Leonardo Da Vinci British Society of Antimicrobial Therapy University of Malaysia/Imperial College Prostate Action PCUK Sasakawa foundation
- Imperial College Medical School Research award, 2012
- Foulkes fellowship for excellence in academic medicine, 2012-2015
- Japanese Society for Promoting Science invitation fellowship, 2012
- Harold Hyam Wingate Foundation Medical Research award, 2011
- BACR AstraZeneca Young Scientist Frank Rose Award and Lecture at NCRI, 2011
- Wellcome Trust Value in People award, 2011 Finalist of Medimmune abstract competition,2009
- EACR Mike Price young scientist award, 2005
- 1st prize for the oral presentation, DIWOL congress, 2005
- “Best presentation” award, Forum of Young Scientists of the 29th FEBS congress, 2004
- M.Sc. Distinction, 2000
- American Journal of Cancer Research - Associate Editor
- Journal of Cancer, Therapeutics and Research - Associate Editor
- Oncology Discovery - Editorial Board Member
- World Journal of Methodology -Editorial Board Member
- New Journal of Science - Editorial Board Member